LXRX LEXICON PHARMACEUTICALS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1062822 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-45.6%
TTM net income YoY9.1%
TTM EPS YoY21.1%
Revenue 3-yr CAGR317.1%
Net income 3-yr CAGR—
Margins
Gross margin98.9%
Operating margin-147.4%
Net margin-161.8%
FCF margin—
EBITDA margin-146.3%
Returns
ROE-43.9%
ROA-27.8%
ROIC (approx.)-33.3%
Asset turnover0.17x
Leverage & solvency
Liabilities / assets32.3%
Debt / equity0.32x
Current ratio10.63x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.79x
Accruals ratio-5.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $49.80M | $31.08M | $1.20M | $139,000 | $298,000 |
| Cost of revenue | $274,000 | $616,000 | $85,000 | $0 | $0 |
| Gross profit | $49.53M | $30.46M | $1.12M | $139,000 | $298,000 |
| R&D expense | $61.12M | $84.48M | $58.89M | $52.82M | $55.05M |
| SG&A expense | $37.32M | $143.10M | $113.98M | $48.08M | $32.34M |
| Operating income | -$48.91M | -$197.12M | -$171.75M | -$100.76M | -$87.09M |
| Interest expense | — | — | — | $2.78M | $802,000 |
| Pretax income | — | — | — | — | -$87.76M |
| Income tax | — | $0 | $0 | $0 | $0 |
| Net income | -$50.34M | -$200.40M | -$177.12M | -$101.94M | -$87.76M |
| EBITDA | -$48.29M | -$196.58M | -$171.20M | -$100.33M | -$86.80M |
| EPS (basic) | -0.14 | -0.63 | -0.80 | -0.62 | -0.60 |
| EPS (diluted) | -0.14 | -0.63 | -0.80 | -0.62 | -0.60 |
| Weighted avg. shares (diluted) | 363.05M | 320.03M | 221.13M | 165.73M | 145.65M |
| Balance sheet | |||||
| Cash & equivalents | $34.33M | $66.66M | $22.46M | $46.34M | $64.06M |
| Short-term investments | $61.90M | $171.30M | $147.56M | $92.01M | $22.68M |
| Receivables | $2.38M | $3.47M | $1.01M | $28,000 | $14,000 |
| Inventory | $281,000 | $231,000 | $381,000 | $0 | — |
| Current assets | $101.89M | $246.19M | $176.55M | $140.87M | $88.92M |
| PP&E, net | $1.86M | $2.48M | $1.99M | $2.07M | $1.18M |
| Goodwill | $44.54M | $44.54M | $44.54M | $44.54M | $44.54M |
| Total assets | $184.99M | $298.42M | $229.43M | $194.30M | $136.91M |
| Current liabilities | $20.87M | $45.25M | $31.55M | $23.17M | $22.12M |
| Short-term debt | $4.59M | $0 | — | — | $0 |
| Long-term debt | $49.41M | $100.30M | $99.51M | $48.58M | $0 |
| Total debt | $54.00M | $100.30M | $99.51M | $48.58M | $0 |
| Total liabilities | $77.45M | $152.47M | $136.32M | $77.17M | $23.31M |
| Shareholders' equity | $107.54M | $145.95M | $93.11M | $117.12M | $113.59M |
| Net debt | $19.68M | $33.64M | $77.04M | $2.23M | -$64.06M |
| Shares outstanding | 365.85M | 363.02M | — | — | — |
| Cash flow statement | |||||
| Operating cash flow | -$67.85M | -$178.78M | -$161.90M | -$88.85M | -$87.02M |
| Capital expenditure | $0 | $1.03M | $470,000 | $1.33M | $1.22M |
| Free cash flow | -$67.85M | -$179.81M | -$162.37M | -$90.18M | -$88.24M |
| Investing cash flow | $113.02M | -$15.38M | -$49.94M | -$71.08M | $2.11M |
| Financing cash flow | -$48.50M | $238.35M | $187.96M | $142.21M | $22.71M |
| Depreciation & amortization | $621,000 | $534,000 | $554,000 | $427,000 | $292,000 |
| Stock-based compensation | $12.52M | $13.50M | $14.34M | $11.52M | $10.58M |
| Share buybacks | — | $1.73M | $824,000 | $864,000 | $2.67M |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.